Interim losses widen at Kromek as costs overshadow soaring revenue
Kromek on Wednesday reported a widened loss due to margin pressure, though revenue surged as the company began to deliver on high value contracts.
FTSE AIM All-Share
755.49
16:15 23/04/24
Health Care Equipment & Services
11,713.81
16:00 23/04/24
Kromek Group
7.38p
15:39 23/04/24
The detection technology supplier booked a loss before tax of £2.7m for the six months ended 31 October, compared with a loss of £2.1m in the same period last year, as gross margin declined from 67% to 58%.
Kromek attributed this to a lower proportion of research & development revenue, which had been disproportionately high in the first half of the prior year due to the relocation of its US factory operations to a new purpose-built site in Pittsburgh.
Operating costs rose by 17% to £5.2m due to recruitment of new staff and a marketing expenses.
Meanwhile, turnover leapt by 43% to £5.3m after the AIM traded company said it delivered a number of high value, multi-year contracts with commercial and government customers across nuclear detection, medical imaging and security screening.
Product sales, which accounted for 82% of revenue, leapt by 53% following an increase in adoption of Kromek's next-generation medical imaging products and an expansion of applications for its D3S nuclear detection platform.
Chief executive Arnab Basu said: "We continue to experience growing demand for our flagship products, which is expected to convert to further orders. As a result, the group has visibility of 90% of expected revenue for FY 2019/20 based on delivery of the contracts already won and supported by a strong and increasing pipeline.
"The board expects to deliver significant revenue growth and EBITDA profit for full year in line with market expectations."
Kromek shares were up by 8.12% at 18.65p at 1003 GMT.